Levonicopto

Levofloxacin, the active ingredient in Levonicopto, is a fluoroquinolone antibiotic presented as an ophthalmic solution for ocular use. It treats bacterial conjunctivitis, bacterial keratitis and other ocular bacterial infections in patients requiring topical eye therapy.

GNH USA supplies Levonicopto as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levonicopto is a fluoroquinolone eye drop indicated for bacterial infections of the eye surface and cornea.

- Bacterial conjunctivitis: reduces bacterial load and accelerates resolution of redness and discharge. - Bacterial keratitis: eradicates causative organisms and promotes corneal healing. - Other ocular bacterial infections: provides broad‑spectrum coverage for Gram‑negative and Gram‑positive pathogens affecting the eye.

Levonicopto may cause local ocular reactions and, rarely, systemic hypersensitivity.

Common Side Effects: - Stinging or burning sensation upon instillation. - Redness of the conjunctiva. - Transient blurred vision. - Foreign‑body sensation. - Mild itching or irritation. - Increased tearing.

Serious or Rare Side Effects: - Severe allergic reaction (e.g., angioedema, anaphylaxis). - Corneal ulceration or perforation. - Significant visual loss. - Persistent eye pain or swelling. - Stevens‑Johnson syndrome involving the eye. - Toxic epidermal necrolysis affecting ocular tissues.

Before prescribing Levonicopto, consider the following safety measures.

- Pregnancy: safety not established; use only if clearly needed. - Breastfeeding: unknown excretion; weigh benefits against potential risks. - Contact lens wearers: remove lenses before and for at least 15 minutes after instillation. - Concurrent ocular surgery: avoid use immediately before or after procedures unless directed. - Known fluoroquinolone allergy: contraindicated. - Store at room temperature: keep in original container, protect from light and moisture.

Levonicopto may interact with systemic or topical agents; monitor patients accordingly.

Major Interactions (Avoid): - Systemic fluoroquinolones: additive risk of tendon rupture and QT prolongation. - Live vaccines: may diminish vaccine efficacy.

Moderate Interactions (Monitor Closely): - Anticholinergic eye drops: may reduce drug absorption. - Topical corticosteroids: increased risk of secondary infection. - Non‑steroidal anti‑inflammatory eye drops: may affect corneal healing. - Other ophthalmic antibiotics: potential for antagonism or reduced efficacy.